Fast track designation allows Alphamab Oncology to interact with the FDA for guidance, potentially expediting approval ...
Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug ...
IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per planLAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ...
Faeth Therapeutics today announced results from the international DICE trial, a randomized phase 2 study of sapanisertib ...
TipRanks on MSN
AstraZeneca’s New Study on AZD5335: A Potential Game-Changer in Ovarian Cancer Treatment
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca has announced a new clinical study titled A Randomised, ...
MedPage Today on MSN
Checkpoint Blockade Finally Breaks Through in Ovarian Cancer
BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall ...
Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Phase 1b/2 ...
Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to ...
Even after Merck & Co.’s Keytruda has climbed to the top of the industry’s sales charts and racked up dozens of FDA-a | A Keytruda-based regimen has shown a statistically significant overall survival ...
Nomograms have a strong reputation as reliable predictive models that simplify statistical prediction models and guide personalized treatment to formulate preventive measures for various diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback